1086 A phase II study of gemcitabine with cisplatin in patients with non-small cell lung cancer

摘要: In a phase II study of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), gemcitabine was given at dose 1000 mg/m 2 weekly for 3 weeks (days 1, 8 and 15 followed by 1 week rest) cisplatin 100 mg/m on day gemcitabine—this all consisting cycle chemotherapy. The had no prior chemotherapy, were WHO performance status 0–2 measurable disease CT scan. To date, 38 are available analysis whom 35 evaluable response as they have received least All toxicity. mean patient age 56 years (range, 35–74 years) the proportion stage IIIa IIIb IV 29%, 35% 36%. median 4 cycles A complete observed in (3%) partial (43%) an overall rate 46%. grade increase serum creatinine, occurred 11% 3% respectively. leukopenia 24% 0%, thrombocytopenia 19% These findings compatible higher combination drugs than either drug singly moderate